-
Dyngo-4a for Reliable Endocytosis and Viability Assays
2026-09-23
A practical guide to using Dyngo-4a (SKU B5997) to investigate dynamin-dependent endocytosis without mistaking trafficking effects for cytotoxicity. It covers assay controls, dose and solvent considerations, interpretation of potency data, and the limits of applying dynamin inhibition to lipid nanoparticle workflows.
-
PA-824 Mechanism in Tuberculosis Research
2026-09-23
PA-824 is a bicyclic nitroimidazole derivative and tuberculosis research compound with activity against replicating and non-replicating Mycobacterium tuberculosis. Evidence supports a dual mechanism involving mycolic-acid biosynthesis and respiratory terminal oxidases, but catalog potency values must be interpreted with assay conditions.
-
Caged Bioluminescent Probe for Immunoproteasome
2026-09-22
The reference study presents a cleavable activity-based bioluminescent probe designed to report immunoproteasome β5i activity in cells and through a tissue-mimicking barrier. Its synthesis and plate-reader workflow provide a practical platform for studying immunoproteasome biology, screening small-molecule interactors, and eventually adapting luminescent readouts to disease-relevant models.
-
6-FAM SE as a Decision Tool for Fluorescent Assays
2026-09-22
6-FAM SE supports durable amine-directed labeling, but its greatest value comes from matching its chemistry to the assay architecture. This article explains how to use 6-Carboxyfluorescein N-hydroxysuccinimide ester alongside lessons from a modular melanoma nanomedicine study without confusing fluorescence tracking with therapeutic function.
-
KR-12 Design Principles and Antimicrobial Applications
2026-09-21
The reference review presents KR-12 as the smallest antibacterial fragment of human LL-37 and maps how sequence engineering, formulation, and biomaterial immobilization can tune its activity. Its practical significance lies in combining membrane-directed antibacterial effects with anti-biofilm, endotoxin-neutralizing, and immune-regulatory functions while emphasizing the limits of translating heterogeneous peptide studies into therapies.
-
HyperScribe™ Kit II for mRNA Synthesis
2026-09-21
Explore how an mRNA synthesis kit can support cap, poly(A), and T7-based workflows for inflammatory disease research. This article translates a fibroblast–LNP study into practical decisions for designing translational mRNA assays.
-
Neuromedin S (rat): Workflow and QC Guide
2026-09-20
Neuromedin S (rat), SKU B5466, provides a defined endogenous peptide agonist for controlled neuromedin U receptor and GPCR/G protein signaling workflows. This guide covers preparation, assay controls, and stability boundaries; the reagent is for research use only and should not be used for diagnostic, therapeutic, or clinical interpretation.
-
HBTU to Translational Immunoproteasome Probes
2026-09-19
HBTU can help translational researchers connect reproducible peptide bond formation with activity-based immunoproteasome probe development. This article explains the chemistry, assay implications, workflow controls, and realistic boundaries between a peptide coupling reagent, a research tool, and clinical translation.
-
HBTU for Peptide Synthesis: Mechanism and Limits
2026-09-18
HBTU, also called 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, is a peptide coupling reagent for carboxylic acid activation and peptide bond formation. This article explains its reaction logic, solid-phase peptide synthesis workflow, storage boundaries, and the limits of connecting HBTU chemistry with enzyme-responsive cancer-selective peptides.
-
Nurr1 Neurogenetic Gradients in the Rat Claustrum
2026-09-18
Fang, Wang, and Naumann mapped when Nurr1-positive neurons arise in the rat claustrum and lateral cortex, resolving regional differences that were difficult to distinguish in earlier birth-dating studies. Their combination of developmental Nurr1 expression mapping with EdU-based birth dating reveals sequential neurogenesis and previously underappreciated ventral-to-dorsal and posterior-to-anterior gradients.
-
KR-12: From Membrane Activity to Colitis Evidence
2026-09-17
KR-12 human antimicrobial peptide research spans membrane disruption, microbiota changes, and inflammation control. This evidence-led article explains how to translate KR-12 findings into better assay design without confusing antimicrobial potency with host-response effects.
-
LL-37 Fragments Against MDR Acinetobacter Biofilms
2026-09-17
The reference study evaluates LL-37 and three fragments, including KR-12, against multidrug-resistant Acinetobacter baumannii. Its main contribution is to connect rapid bactericidal activity with inhibition of adherence and established biofilms, while also showing that fragment performance varies substantially by assay and endpoint.
-
HBTU Chemistry for Peptide Probe Design
2026-09-16
Explore how HBTU enables controlled peptide bond formation and supports the synthesis of assay-ready proteasome probes. This guide connects carboxylic acid activation and racemization-resistant coupling with practical decisions in bioluminescent peptide assay development.
-
CX-5461 in Cervical Cancer: Mitotic Catastrophe
2026-09-16
The reference study shows that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth through a DNA damage response that forces damaged cells into abnormal mitosis and mitotic catastrophe. Its enhancement of cisplatin sensitivity provides a mechanistic rationale for investigating Pol I inhibition in treatment-resistant cervical cancer models.
-
Metabolite Binding and TET2 Regulation: A Protocol Guide
2026-09-15
Zhang and colleagues present an integrated workflow that combines biochemical TET2 activity assays with saturation transfer difference NMR to distinguish metabolite binding from functional regulation. The protocol validates known TET2 activators and inhibitors while providing a practical route for discovering additional metabolic regulators, including glyoxylate.